Kane Biotech to Present at Symposium on Advanced Wound Care Fall Forum
Company presenting technologies for improving patient outcomes in wound careWINNIPEG, Manitoba, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc....
Antimicrobial
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022
MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and...
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023LEXINGTON, Mass., Oct. 13, 2022...
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of...
T2 Biosystems Announces Reverse Stock Split Effective Today
TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2022LEXINGTON, Mass., Oct. 12, 2022 (GLOBE...
Synthetic Biologics Rebrands as Theriva Biologics
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022...
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine ResearchPRINCETON, N.J.,...
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed...
Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek’s Management TeamBOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) --...
BioLife Sciences Inc. (OTC: BLFE) Enters Into Negotiations for Exclusive Licensing Deal With Canadian Firm
HENDERSON, NV, Sept. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences (OTCPK: BLFE) is pleased to announce that...
Building on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.
• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition...
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero...
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low...
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis...
Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicineRESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) --...
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05,...
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on...
OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunityServices at launch include rapid...